RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
The purpose of this study is to determine if adding the chemotherapy agent cetuximab to radiation therapy will be beneficial in patients with head and neck cancer who have recently been treated surgically.
Squamous cell carcinoma (SCC) of the head and neck that has been or will be treated surgically.
Adults diagnosed with head and neck cancer. Surgery must be completed within 7 weeks of enrollment. Blood work, tumor scans, and tumor tissue testing will be performed and reviewed to determine eligibility.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Treatment in this study will last 6 to 11 weeks.
Will Stott, Senior Research Associate
Radiation Therapy Oncology Group (RTOG)